← Back to Clinical Trials
Recruiting NCT05660148

NCT05660148 Influence of Resentment and Forgivingness on Quality of Life in People Living With HIV

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05660148
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Forgiveness
Study Type OBSERVATIONAL
Enrollment 206 participants
Start Date 2024-05-06
Primary Completion 2026-11-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 206 participants in total. It began in 2024-05-06 with a primary completion date of 2026-11-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Life stress is strongly associated with poor mental and physical health and its effects explain significant morbidity and mortality. Forgiveness is one of the factors that can influence the effects of stress on health. By definition, forgiveness is the release of negative feelings, emotions, and behaviors - and possibly the release of positive feelings - toward an offender. Numerous studies have shown that forgiveness is associated with several mental and physical health benefits. The literature argues that high levels of propensity to forgive (trait) predispose that person to experience forgiveness (state) more often. In other words, a stronger forgiving disposition is believed to increase the experience of forgiveness, which, in turn, mitigates the negative effects of stress. Forgiveness is therefore a coping style that can play a beneficial role in the stress-health relationship. Patients living with HIV (PLHIV) are patients particularly exposed to stress, not only because of their chronic pathology but also because of the stigma attached to this disease. Very few studies have studied the impact of forgiveness (state or trait) on the physical health of PLHIV and even fewer the impact of an intervention promoting the disposition to forgive. The objective of this prospective observational monocentric study is to show in a very secular country that forgiveness has an effect on well-being as well as on other health parameters.

Eligibility Criteria

Inclusion Criteria: * Belonging to the PLHIV followed at the Amiens University Hospital, not likely to move within the year * Possibility of follow-up in teleconsultation (usual support of the service) * Benefiting from a social security scheme * Consent to participate in the research Exclusion Criteria: * Erratic follow-up (non-compliance, predictable move) or moribund patient * Illiterate or not speaking french

Contact & Investigator

Central Contact

Jean-Philippe Lanoix, Pr

✉ lanoix.jean-philippe@chu-amiens.fr

📞 03 22 08 80 51

Frequently Asked Questions

Who can join the NCT05660148 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Forgiveness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05660148 currently recruiting?

Yes, NCT05660148 is actively recruiting participants. Contact the research team at lanoix.jean-philippe@chu-amiens.fr for enrollment information.

Where is the NCT05660148 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT05660148 clinical trial?

NCT05660148 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 206 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology